NEW YORK, July 7, 2015 /PRNewswire/ --
Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed a registration statement on Form F-1/A with the Securities and Exchange Commission, in connection with the proposed public offering of ordinary stock and listing on the NASDAQ Stock Market. The number of American Depositary Shares, representing ordinary shares, to be offered, and the price range for the offering have not yet been determined. An Investor Roadshow will be conducted in the US during July 2015.
(Photo: http://photos.prnewswire.com/prnh/20150703/228185 )
Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, which is expected to close on July 30, 2015 at the latest, subject to customary closing conditions.
"This is a very exciting time for Oasmia, as we progress through the final stages of the filing and NASDAQ listing process to create exposure to new financial markets," said Julian Aleksov, Executive Chairman of Oasmia.
Oasmia seeks increased visibility within both the pharmaceutical sector and mainstream markets, following what many perceive to be a significant expansion of cancer treatments. Recently, Abraxane, a treatment similar to Oasmia's patented product Paclical®, was acquired for $2.9 billion by Celgene Inc. Oasmia believes its family of products is positioned for significant sales growth, due to its track record of novel technology, presenting positive clinical data and its product pipeline.
Following a year where worldwide spending on cancer drugs surpassed $100 billion, an increase of 10% from 2013, Oasmia anticipates establishing a US-based sales platform for its products. The animal health industry has continued to grow over the past decade, reaching nearly $25 billion in 2014. Specifically, the market for veterinary oncology shows tremendous upside as well, exemplified by the approximately 25% of dogs that will develop a tumor during their lifetime and owners' increased interest in committing to treatments for their companions.
The offering of these securities will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from Vallongatan 1, Telephone: +46 18 50 54 40, Facsimile: +46 18 51 08 73 or by Emailing: email@example.com. In addition, the registration statement, including the prospectus, is available to the public at http://www.sec.gov. or http://www.oasmia.com
SOURCE Oasmia Pharmaceutical AB